ArticleHepatology international2024

Is TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors superior to TACE plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: the debate continues.

Shiye Yang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.